All drug manufacturers, including Novo Nordisk and Teva Pharmaceuticals , whose medicines are part of the second round of ...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic ...

Explore why Recursion Pharmaceuticals' AI-driven drug discovery faces challenges in revenue growth, governance, and investor ...

ILUVIEN now approved for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) in addition to ...

Fennec Pharmaceuticals shares were down after the company reported fourth-quarter results. The stock was recently down 10% to $6.20 and is down about 2% this year.